secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kymera Therapeutics, Inc. (KYMR)
CIK:        0001815442
Form:       8-K
Filed at:   2024-10-31T23:59:59+00:00
Accession:  0000950170-24-119245
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kymera posts Q3 net loss $62.5M; initiates STAT6 degrader Phase 1; shifts focus to immunology
--------------------------------------------------------------------------------

- Net loss $62.5M in Q3 2024 vs $52.9M in Q3 2023; collaboration revenue $3.7M from Sanofi.
- Initiated Phase 1 dosing for KT-621 (STAT6 degrader); Phase 1 data expected H1 2025.
- Sanofi expands KT-474 (IRAK4) Phase 2 HS/AD trials to dose-ranging Phase 2b; primary completion mid-2026.
- Selected KT-295 (TYK2 degrader) as development candidate; Phase 1 start in H1 2025.
- Cash $911M as of Sep 30, 2024; runway into mid-2027; will only advance oncology with partner.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815442/000095017024119245/0000950170-24-119245-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815442/000095017024119245/kymr-20241031.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-119245

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer